Global Gout Therapeutics Market -2020-2027
|痛風治療藥的全球市場:2020年∼2027年 Global Gout Therapeutics Market -2020-2027|
|出版日期: 2020年08月20日||內容資訊: 英文|
Gout s a type of inflammatory arthritis caused by the overabundance of uric acid in the body which is due to either producing too much or excreting too little. Gout can be acute and chronic. The acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings ( known as tophi) can form on the joints which are made of uric acid and grows large, even to the point of breaking through the skin.
The global Gout Therapeutics market size was worth $ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Gout Therapeutics Market Dynamics
The global gout therapeutics market is impacted by several factors such as rising prevalence of gout globally due to change in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and consumption of several medications such as diuretics.
Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals, in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis, joint damage, tophi formation, and urate nephropathy. According to the Australian Bureau of Statistics and National Health Survey 2017-2018, estimated that 187,000 Australians (0.8% of the population) suffer from gout condition. Gout is more common in males than females, almost 9 in 10 (87%) people with gout are males. Hence, the demand for gour treatment is increasing, which is expected to show growth over the forecast period.
In addition, increasing government initiatives and awareness towards gout cause and treatment is expected to boost the growth of the market. For instance, in May 2016, the Arthritis Foundation and Takeda Pharmaceuticals USA Inc. launched the Let's Speak Gout program, which offers tools for health care professionals and patients to make more effective gouty arthritis management a priority.
In May 2018, Horizon Pharma plc marked Gout Awareness Day by launching Gout Revealed, which was created to spotlight real-life stories of people living with uncontrolled gout. People living with uncontrolled gout gets the opportunity to share their own story through the website, which will be updated throughout the year to help educate others.
Also, rising research and development to introduce new therapeutic treatment for gout is driving the growth of the market over the forecast period. For instance, on October 29th 2019, Researchers at the Washington State University Health Sciences Spokane and elsewhere have identified a new therapeutic target for the treatment of gout. The research lays the foundation for the development of new treatment strategies that could significantly improves the quality of life of millions of people around the world who suffer from the condition. In the United States alone, gout affects an estimated 8.3 million people or about 4 per cent of the population.
With the ongoing COVID-19 pandemic, several companies are testing their drugs for its treatment. For instance, on June 22nd 2020, anti-viral drug Favipiravir (Fabiflu) was approved for the treatment of mild to moderate COVID-19 patients will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.
However, the growth of the market is likely to hamper by side effects caused by grout drugs. For instance, the side effects of allopurinol include a rash and low blood counts. Febuxostat side effects include rash, nausea, reduced liver function and an increased risk of heart-related death. Also, side effects of corticosteroids may include mood changes, increased blood sugar levels and elevated blood pressure.
Gout Therapeutics Market Segment Analysis
By drug class, the gout therapeutics market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), antihyperuricemic agents (urate-lowering drugs), corticosteroids, colchicine, and others. Among these, the antihyperuricemic agents segment is expected to grow with the highest CAGR over the forecast period. Some of the most common urate-lowering drugs used are xanthine oxidase inhibitors (allopurinol and febuxostat), uricases (pegloticase and rasburicase), and uricosuric medications (benzbromarone, probenecid, and sulfinpyrazone). With rising preference and of these drugs for the treatment of gout is boosting the growth of the market over the forecast period.
On the other hand, the NSAIDs, corticosteroids, and colchicine are majorly used to treat acute gout. The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the gout therapeutics market in 2019, owing to availability of these drugs at a lower cost compared to other drugs, high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack. NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. Stronger NSAIDs like indomethacin and celecoxib are prescribed by the doctor.
Colchicine are considered to be second-line therapy, used in patients unable to tolerate NSAIDs. These drugs have the ability to inhibit acute inflammatory response by restraining neutrophil adhesion, chemotaxis, and motility. On March 2nd 2020, Avion Pharmaceuticals launched the Gloperba (colchicine, a ready-to-use solution for oral administration for prophylaxis of gout flares in adults. The approval was based on evidence from published literature supporting the efficacy of colchicine in patients with chronic gout. In 2 randomized clinical trials, the treatment with colchicine 0.6mg twice daily was associated with decrease in the frequency of gout flares.
By disease type, the chronic gout is dominating the gout therapeutics market. This segment encompasses urate-lowering agents such as xanthine oxidase inhibitor and uricosuric agents. Introduction of urate-lowering drugs and expected entry of pipeline drugs are likely to drive the market at the fastest rate during the forecast period.
Gout Therapeutics Market Geographical Analysis
North America is dominating the global gout therapeutics market accounting for the largest market share in 2019, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals in the U.S. Also, the research and development of new drugs for the treatment of gout is expected to show dominance over the forecast period. In June 2020, Pharma major Dr Reddy's Laboratories has launched the generic Colchicine tablets which are used for prevention and treatment of acute gout flares in the US market.
Also, in December 2019 Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial is evaluating the superiority of a once-monthly dose of Selecta's lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.
The Asia Pacific region is expected to grow at the fastest growth rate over the forecast period owing to the diversified patient pool, growing investment by major players with local manufacturers and hospital chains in growing countries such as India, China, South Korea, and other South Asian countries. According to the Australian Institute of Health and Welfare, in 2015-2016, the gout cost the Australian health system an estimated USD 176.5 million, representing 1.4% of disease expenditure on musculoskeletal conditions and 0.2% of total disease expenditure. In addition, changing lifestyle with rising prevalence of smoking & alcohol consumption are expected to boost the incidence of gout over the period.
Gout Therapeutics Market Competitive Landscape
The gout therapeutics market is fragmented and highly competitive and consists of several major players. The market share is dominated by few major players and few emerging companies which are expected to enter the market over the forecast period. Some of the major players of the market are Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, Mylan, among others. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Gout Therapeutics market globally. For instance,
The global gout therapeutics market report would provide an access to an approx. 61 market data table, 54 figures and 280 pages.
LIST NOT EXHAUSTIVE